|
1.
|
|
9 p, 1.3 MB |
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies
/
Robak, Tadeusz (Medical University of Lodz) ;
Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Barr, Paul M. (University of Rochester Cancer Center) ;
Owen, Carolyn (University of Calgary) ;
Bairey, Osnat (Tel Aviv University) ;
Hillmen, Peter (St. James's Institute of Oncology) ;
Simpson, David (North Shore Hospital) ;
Grosicki, Sebastian (Silesian Medical University) ;
Devereux, Stephen (King's College Hospital NHS Foundation Trust) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Quach, Hang (St. Vincent's Hospital) ;
Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ;
Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ;
Stevens, Don A. (Norton Cancer Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gill, Devinder S. (Princess Alexandra Hospital) ;
Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Gribben, John G. (Queen Mary University of London) ;
Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Kipps, Thomas J (University of California San Diego) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 -  10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410
|
|
|
2.
|
|
6 p, 3.4 MB |
Outcome of infection with omicron -2 variant in patients with hematological malignancies : An survey report
/
Blennow, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Salmanton-García, Jon (University of Cologne) ;
Nowak, Piotr (Karolinska Institutet (Suecia)) ;
Itri, Federico (San Luigi Gonzaga Hospital - Orbassano) ;
van Doesum, Jaap A (Department of Hematology, University Medical Center Groningen) ;
López-García, Alberto (Fundacion Jimenez Diaz University Hospital) ;
Farina, Francesca (Istituto Scientifico San Raffaele) ;
Jakšić, Ozren (University Hospital Dubrava) ;
Pinczés, László Imre (University of Debrecen) ;
Bilgin, Yavuz M. (ADRZ) ;
Falces-Romero, Iker (Instituto de Salud Carlos III) ;
Jiménez, Moraima (Vall d'Hebron Institut d'Oncologia) ;
Ormazabal-Vélez, Irati (Complejo Hospitalario de Navarra) ;
Weinbergerová, Barbora (University Hospital Brno (República Txeca)) ;
Duléry, Rémy (Sorbonne Université) ;
Stojanoski, Zlate (University of Skopje) ;
Lahmer, Tobias (TU München) ;
Fernández, Noemí (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Hernández-Rivas, José-Ángel (Hospital Universitario Infanta Leonor) ;
Petzer, Verena (Medical University of Innsbruck) ;
De Jonge, Nick (Vrije Universiteit Amsterdam) ;
Glenthøj, Andreas (Copenhagen University Hospital Rigshospitalet) ;
De Ramón-Sánchez, Cristina (Instituto de Investigación Biomédica de Salamanca) ;
Biernat, Monika M. (Wroclaw Medical University) ;
Fracchiolla, Nicola (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Aujayeb, Avinash (Northumbria Healthcare) ;
Van Praet, Jens (AZ Sint-Jan Brugge-Oostende AV) ;
Schönlein, Martin (University Medical Center Hamburg-Eppendorf) ;
Méndez, Gustavo-Adolfo (Hospital Escuela de Agudos Dr. Ramón Madariaga) ;
Cattaneo, Chiara (ASST-Spedali Civili) ;
Guidetti, Anna (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Sciumè, Mariarita (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Ammatuna, Emanuele (University Medical Center Groningen) ;
Cordoba, Raul (Fundacion Jimenez Diaz University Hospital) ;
García-Poutón, Nicole (Hospital Clínic i Provincial de Barcelona) ;
Gräfe, Stefanie (Universitätsklinikum Hamburg Eppendorf) ;
Cabirta, Alba (Vall d'Hebron Institut d'Oncologia) ;
Wolf, Dominik (Medical University of Innsbruck) ;
Nordlander, Anna (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
García-Sanz, Ramón (Instituto de Investigación Biomédica de Salamanca) ;
Delia, Mario (AOUC Policlinico) ;
Berg Venemyr, Caroline (Copenhagen University Hospital Rigshospitalet) ;
Brones, Clara (Centre Hospitalier de Versailles) ;
Di Blasi, Roberta (Hopital Saint Louis) ;
De Kort, Elizabeth (Radboud University Medical Center) ;
Meers, Stef (AZ KLINA) ;
Lamure, Sylvain (University Hospital of Montpellier (França)) ;
Serrano, Laura (Hospital Universitario de Cabueñes (Gijón)) ;
Merelli, Maria (ASU FC Udine Hospital) ;
Coppola, Nicola (Universitry of Campania) ;
Bergantim, Rui (Centro Hospitalar e Universitário de São João) ;
Besson, Caroline (Centre Hospitalier de Versailles) ;
Kohn, Milena (Centre Hospitalier de Versailles) ;
Petiti, Jessica (University of Turin) ;
Garcia-Vidal, Carolina (Hospital Clínic i Provincial de Barcelona) ;
Dargenio, Michelina ("Vito Fazzi" Hospital) ;
Danion, François (CHU de Strasbourg) ;
Machado, Marina (Hospital General Universitario Gregorio Marañón) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Hoenigl, Martin (Medical University of Graz) ;
Dragonetti, Giulia (Fondazione Policlinico Universitario Agostino Gemelli) ;
Chai, Louis Yi Ann (National University Health System) ;
Kho, Chi Shan (Pamela Youde Nethersole Eastern Hospital) ;
Bonanni, Matteo (Università Cattolica del Sacro Cuore) ;
Liévin, Raphaël (Hopital Saint Louis) ;
Marchesi, Francesco (IRCCS Regina Elena National Cancer Institute) ;
Cornely, Oliver A. (German Centre for Infection Research) ;
Pagano, Livio (Università Cattolica del Sacro Cuore) ;
Universitat Autònoma de Barcelona
2022 - 10.1002/ajh.26626
American Journal of Hematology, Vol. 97 (june 2022) , p. E312-E317
|
|
|
3.
|
|
469.5 KB |
Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes
/
Martin, Roman (University Medical Center Göttingen) ;
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ganster, Christina (University Medical Center Göttingen) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Dierks, Sascha (University Medical Center Göttingen) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gómez-Marzo, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
De Haro, Nuri (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Solanes, Neus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Shirneshan, Katayoon (University Medical Center Göttingen) ;
Flach, Johanna (University Medical Center Göttingen) ;
Braulke, Friederike (University Medical Center Göttingen) ;
Schanz, Julie (University Medical Center Göttingen) ;
Kominowski, Arkadiusz (University Medical Center Göttingen) ;
Stromburg, Martin (University Medical Center Göttingen) ;
Brockmann, Alina (University Medical Center Göttingen) ;
Trümper, Lorenz (University Medical Center Göttingen) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Haase, Detlef (University Medical Center Göttingen) ;
Universitat Autònoma de Barcelona
2018 - 10.1002/ajh.25089
American Journal of Hematology, Vol. 93 (april 2018) , p. E152-E154
|
|
|
4.
|
|
11 p, 1.4 MB |
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
/
Timmerman, John (UCLA Medical Center) ;
Herbaux, Charles (Centre Hospitalier Régional Universitaire de Lille) ;
Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ;
Zelenetz, Andrew D. (Memorial Sloan Kettering Cancer Center) ;
Houot, Roch (Unité dʼInvestigation Clinique) ;
Neelapu, Sattva S. (The University of Texas MD Anderson Cancer Center) ;
Logan, Theodore (Indiana University) ;
Lossos, Izidore S. (Sylvester Comprehensive Cancer Center) ;
Urba, Walter (Providence Cancer Center) ;
Salles, Gilles (Université de Lyon) ;
Ramchandren, Radhakrishnan (Karmanos Cancer Institute) ;
Jacobson, Caron (Harvard Medical School) ;
Godwin, John (Providence Cancer Center) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Lathers, Deanne (Bristol-Myers Squibb) ;
Liu, Yali (Bristol-Myers Squibb) ;
Neely, Jaclyn (Bristol-Myers Squibb) ;
Suryawanshi, Satyendra (Bristol-Myers Squibb) ;
Koguchi, Yoshinobu (Providence Cancer Center) ;
Levy, Ronald (Stanford University School of Medicine)
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. [...]
2020 - 10.1002/ajh.25757
American Journal of Hematology, Vol. 95 (february 2020) , p. 510-520
|
|
|
5.
|
|
11 p, 1.8 MB |
Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
/
Munir, Talha (St. James's Hospital ( Dublín, Irlanda)) ;
Brown, J. R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ;
Barr, Paul M (Wilmot Cancer Institute. University of Rochester Medical Center) ;
Reddy, N. M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, Steven E. (Stanford Cancer Center. Stanford University School of Medicine) ;
Tam, C. S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ;
Mulligan, S. P. (Royal North Shore Hospital) ;
Jaeger, Ulrich (Division of Hematology and Hemostaseology. Medical University of Vienna) ;
Kipps, T. J. (UCSD Moores Cancer Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Montillo, M. (Niguarda Ca' Granda Hospital) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Byrd, J. C. (The Ohio State University Comprehensive Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Dai, Sandra (Pharmacyclics LLC. an AbbVie Company) ;
Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Woyach, J. A. (The Ohio State University Comprehensive Cancer Center) ;
Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
